Mr. Stephen Van Deventer reports

PREVECEUTICAL CLOSES FINAL TRANCHE OF UP-SIZED NON-BROKERED PRIVATE PLACEMENT

Following Preveceutical Medical Inc.'s news releases dated April 2, 2025, April 14, 2025, and April 28, 2025, it has successfully closed the final tranche of its previously announced $700,000 non-brokered private placement. The final tranche comprised 5,279,400 units of the company at a price of three cents per unit, resulting in gross aggregate proceeds of $158,382. In total, Preveceutical has raised $748,383 through the issuance of an aggregate of 24,946,100 units at a price of three cents per unit.

Each unit comprised one common share in the capital of the company and one-half of one share purchase warrant. Each warrant entitles the holder thereof to purchase an additional share at an exercise price of five cents per warrant share for a period of 24 months from the closing of the final tranche, subject to an acceleration right, whereby the expiry date of the warrants may be accelerated if the daily closing price of the shares equals or exceeds eight cents or greater on the Canadian Securities Exchange (CSE) (or such other recognized securities exchange on which the shares may then trade) for a minimum of 10 consecutive trading days, in which event the company may accelerate the expiry of the warrants by giving notice via news release and, in such case, all of the then unexercised warrants will expire on the 30th day after the date on which the news release is disseminated.

In connection with the final tranche closing, the company paid finders' fees to an eligible finder comprising $12,670.56 in cash and issued 422,352 finders' warrants. The finders' warrants are exercisable into one additional share at an exercise price of five cents per share for 24 months from the final tranche closing, subject to the acceleration right.

The company intends to use the aggregate gross proceeds of the final tranche to pay outstanding payables, for operating expenses and for general working capital purposes.

All securities issued in relation to the final tranche are subject to a hold period expiring four months and one day after the final tranche closing, in accordance with applicable securities laws.

About Preveceutical Medical Inc.

Preveceutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. Preveceutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel program; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

We seek Safe Harbor.